FY2028 EPS Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX) Decreased by Analyst

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at HC Wainwright decreased their FY2028 earnings estimates for Travere Therapeutics in a research report issued to clients and investors on Wednesday, April 24th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of $4.29 for the year, down from their previous estimate of $4.66. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.11. The firm had revenue of $45.06 million for the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%.

Several other research firms have also weighed in on TVTX. Wells Fargo & Company increased their price objective on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Friday, February 16th. Piper Sandler increased their price objective on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Thursday, January 18th. Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Finally, Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Travere Therapeutics Price Performance

TVTX opened at $5.26 on Thursday. The firm has a market cap of $400.33 million, a price-to-earnings ratio of -3.27 and a beta of 0.58. Travere Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $22.75. The company’s 50-day moving average price is $7.28 and its 200 day moving average price is $7.65. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88.

Insider Buying and Selling

In related news, CEO Eric M. Dube sold 19,122 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.70, for a total transaction of $166,361.40. Following the completion of the sale, the chief executive officer now directly owns 350,600 shares in the company, valued at $3,050,220. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Eric M. Dube sold 19,122 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.70, for a total transaction of $166,361.40. Following the completion of the sale, the chief executive officer now directly owns 350,600 shares in the company, valued at $3,050,220. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP William E. Rote sold 4,764 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total transaction of $41,494.44. Following the sale, the senior vice president now owns 80,720 shares of the company’s stock, valued at $703,071.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,773 shares of company stock worth $300,625. Corporate insiders own 3.75% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TVTX. SG Americas Securities LLC acquired a new position in Travere Therapeutics in the 3rd quarter worth approximately $1,179,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Travere Therapeutics by 32.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock worth $148,000 after purchasing an additional 4,007 shares during the period. Emerald Advisers LLC boosted its stake in Travere Therapeutics by 64.9% in the 3rd quarter. Emerald Advisers LLC now owns 1,060,302 shares of the company’s stock worth $9,479,000 after purchasing an additional 417,250 shares during the period. Emerald Mutual Fund Advisers Trust boosted its stake in Travere Therapeutics by 44.4% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 764,603 shares of the company’s stock worth $6,836,000 after purchasing an additional 235,085 shares during the period. Finally, Cheyne Capital Management UK LLP acquired a new position in Travere Therapeutics in the 3rd quarter worth approximately $234,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.